News
Med-tech stock Conmed dips ahead of big Q4 report...opportunity?
When Utica, NY-based medical technology company CONMED Corporation (NYSE:CNMD) reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in
4 med tech stocks with improving prognosis for 2024
Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to
Starbucks perks up on margin strength: Are new highs in sight?
Starbucks Corporation (NASDAQ: SBUX) share prices perked up after the FQ1 release and guidance, but new highs are not in sight. The results were mixed, weak relative to the analysts' consensus
Starbucks perks up on margin strength: Are new highs in sight?
Starbucks Corporation (NASDAQ: SBUX) share prices perked up after the FQ1 release and guidance, but new highs are not in sight. The results were mixed, weak relative to the analysts' consensus
Starbucks perks up on margin strength: Are new highs in sight?
Starbucks Corporation (NASDAQ: SBUX) share prices perked up after the FQ1 release and guidance, but new highs are not in sight. The results were mixed, weak relative to the analysts' consensus
Crane can fly to new highs in 2024
Crane (NYSE: CR) is a high-flying stock, having gained 58% since the IPO spin-off and keeping most of it. A recent downshift in analyst sentiment driven by valuation capped gains in January
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 31205%
31.01.24 08:02
London (www.aktiencheck.de, Anzeige)
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 31205%
31.01.24 08:02
London (www.aktiencheck.de, Anzeige)
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in der Krebsforschung - 22% der Patienten vollständig geheilt. Neuer 250% Biotech Hot Stock nach 31205%
31.01.24 08:02
London (www.aktiencheck.de, Anzeige)
United Parcel Service: UPS stock is going down, opportunity?
United Parcel Service (NYSE: UPS) shares fell sharply following the Q4 results and 2024 guidance, confirming resistance at a critical level. The technical signal is bearish and may shave another
Is Airbnb a buy on fee increase, international growth?
Airbnb Inc. (NASDAQ: ABNB) is in a buy range out of a sloppy consolidation that began on July 31.
The Airbnb chart shows the stock’ heavy-volume upside momentum in the January 26 and January 29
AppLovin stock breaks out: App'tizing momentum ahead
From a technical standpoint, identifying a mid-cap stock that has performed as remarkably and consistently over one year as AppLovin (NYSE: APP) might be difficult.
Impressively, over the
Celsius stock finally cools off...analysts warm up to it
With temperatures well below freezing in many parts of Canada, it's only fitting that Celsius Holdings, Inc. (NASDAQ: CELH) is heading north.
Last week, the fitness energy drink maker announced
Celsius stock finally cools off...analysts warm up to it
With temperatures well below freezing in many parts of Canada, it's only fitting that Celsius Holdings, Inc. (NASDAQ: CELH) is heading north.
Last week, the fitness energy drink maker announced
Humana EPS shocker. Are Medicare Advantage plans in jeopardy?
Health insurance carrier Humana Inc. (NYSE: HUM) reported a bombshell when it released its fourth-quarter 2023 earnings report. The company not only missed its estimated EPS by a mile but also
3 defense stocks that could soar on new contracts
The whole world has turned its attention to the escalating conflicts in the Red Sea involving United States and United Kingdom military personnel. While the media may underplay the significance of
3 defense stocks that could soar on new contracts
The whole world has turned its attention to the escalating conflicts in the Red Sea involving United States and United Kingdom military personnel. While the media may underplay the significance of
American Superconductor faster than a speeding bullet on EPS beat
Megawatt-scale power resiliency solutions provider American Superconductor Co. (NASDAQ: AMSC) shares surged 40% on its Q3 2023 earnings report and upside guidance. The computer and technology
American Superconductor faster than a speeding bullet on EPS beat
Megawatt-scale power resiliency solutions provider American Superconductor Co. (NASDAQ: AMSC) shares surged 40% on its Q3 2023 earnings report and upside guidance. The computer and technology
Yes, Colgate-Palmolive can clean its way to a fresh all-time high
Colgate-Palmolive (NYSE: CL) shares are trending higher within a range and have new highs in sight. The Q4 results, guidance and analysts' sentiment suggest it will set a new multi-year high soon
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 15.973%
30.01.24 08:02
London (www.aktiencheck.de , Anzeige)
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 15.973%
30.01.24 08:02
London (www.aktiencheck.de , Anzeige)
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: 22% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 15.973%
30.01.24 08:02
London (www.aktiencheck.de , Anzeige)
Intel Q4 results: A bad sign for tech earnings
Intel's (NASDAQ: INTC) Q4 results and guidance for Q1 were mixed, to say the least, giving ample reason for the market to sell off, but the depths of the correction may have already been plumbed
Intel Q4 results: A bad sign for tech earnings
Intel's (NASDAQ: INTC) Q4 results and guidance for Q1 were mixed, to say the least, giving ample reason for the market to sell off, but the depths of the correction may have already been plumbed